Adverse Event: GSK’s Belimumab Increased Risk of Serious Psychiatric Events Seen in Clinical Trials

Psychiatric

By

Adverse Events Challenging Pharma GSK Pharma Watch Pharmaceutical Psychiatric

The UK government reported that GSK’s Belimumab (Benlysta) have revealed in clinical trials to show an increased risk of depression, suicidal ideation or behavior, or self-injury in patients with systemic lupus erythematosus.  The UK government is warning physicians and investigators to assess patients for these risks before the start of treatment with belimumab.